<DOC>
	<DOCNO>NCT01110707</DOCNO>
	<brief_summary>This prospective , randomise , Phase II , comparative study parallel control evaluate efficacy safety combine treatment recombinant human follicle stimulate hormone ( r-hFSH ) recombinant human luteinizing hormone ( r-hLH ) . The combined treatment administer middle follicular phase subject undergo in-vitro fertilisation ( IVF ) intracytoplasmic sperm injection ( ICSI ) transfer embryo ( ET ) . Few evidence suggest age subject possibility obtain benefit combine use FSH LH . This study design find whether addition r-hLH sixth day stimulation r-hFSH conventional protocol improves assist reproduction term quality recover oocyte , implantation rate pregnancy rate subject .</brief_summary>
	<brief_title>A Randomised , Phase II , Comparative Study With Parallel Control Evaluating Efficacy Safety Combined Treatment Lutropin Alpha Recombinant Human Luteinizing Hormone Middle Controlled Ovarian Stimulation Follicular Phase Women With Reduced Ovarian Reserve</brief_title>
	<detailed_description>Delayed pregnancy woman 35 year important limitation regard success IVF . It represent real challenge assist reproduction due risk achieve unsatisfactory follicular recruitment growth , would result controlled ovarian stimulation ( COS ) . It common practice start COS high dos FSH age subject gonadotropin release hormone ( GnRH ) agonist protocol use . With combination r-hFSH r-hLH COS non-selected group subject undergoing IVF , significant statistical difference obtain respect use r-hFSH alone . The analysis subpopulation deep pituitary suppression require elevated dos r-hFSH indicate use r-hLH positive term quality oocytes increase pregnancy rate . Preliminary data publish favour add r-hLH rescue treatment increase quality oocytes young subject subject IVF , present little response conventional dos FSH , indicate strong suppression endogenous LH . OBJECTIVES - To evaluate efficacy add r-hLH middle follicular phase compare non addition r-hLH subject , subject COS r-hFSH practicing IVF/ICSI ET , term quality oocyte , follicular development , fertilisation oocyte , quality embryos pregnancy rate - To evaluate safety r-hLH combined r-hFSH symptom list objective , include incidence ovarian hyperstimulation syndrome ( OHSS ) , general adverse occurrence local reaction injection area This study perform out-patient basis subject receive one treatment cycle pituitary desensibilization GnRH agonist ( GnRH-a ) . The desensibilization commence middle luteinic phase ( long protocol ) . Once decrease pituitary activity confirm use estradiol ( E2 ) &lt; 50 pg/ml ( 180 pmol/l ) criterion , COS initiate r-hFSH dosage 300-450 IU administer subcutaneously ( sc ) . On Day 6 stimulation ( S6 ) , subject randomly assign additional treatment r-hLH fixed dosage 150 IU continue treated r-hFSH alone . The first dose r-hLH administer late evening day randomisation carry ( S6 ) . The combined treatment r-hLH + r-hFSH treatment r-hFSH alone administer follicular development adequate judge investigator ( evaluated ovarian ultrasound determination serum level E2 ) . A sole injection 250 mcg human recombinant chorionic gonadotropin ( r-hCG ) administer order achieve follicular maturation within 36 hour follow last dose r-hFSH , r-hLH GnRH-a . The r-hCG administer least one follicle reach average diameter &gt; 18 mm follicle diameter &gt; 16 mm E2 level proportional number size follicle present . The oocyte collect 34-38 hour administer r-hCG evaluate fertilised in-vitro ICSI . No 3 embryos implanted Days 2-4 oocyte retrieval ( ovum pick-up ) . The luteinic phase support daily administration natural progesterone via vaginal route , start ovum pick-up ( OPU ) continue moment menstruation pregnancy test ; , subject pregnant , least 30 day obtain positive result laboratory pregnancy test . A monitoring subject carry result treatment record ( pregnancy menstruation ) .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>All subject must meet follow inclusion criterion within 6 month prior start pituitary suppression unless otherwise specify : Premenopausic woman age 35 40 year wish become pregnant Subjects basal serum level ( begin follicular phase , Day 25 ) FSH &lt; 10 IU/l determine within 6 month prior well LH E2 level within normal interval accord standard data area study carry Subjects regular menstrual cycle 2535 day Subjects infertility justifies treatment IVF/ET ICSI Subjects undergoing COS rhFSH use long protocol GnRHa Sperm availability subject 's current partner unless plan use sperm donor Subjects ovaries Subjects uterine cavity capable withstand implantation embryo pregnancy Subjects whose vaginal smear ( PAP ) normal within 3 year prior start stimulation Subjects body mass index ( BMI ) 18 30 time participation study Subjects least 30 day elapse since last dose clomiphene citrate gonadotropin begin treatment GnRHa Subjects negative pregnancy test result use beta human chorionic gonadotropin ( betahCG ) test ( urine blood ) begin treatment GnRHa Subjects willing capable follow protocol entire study Subjects provide informed write consent carry procedure relate study ( part normal medical treatment follow subject ) Subject human immunodeficiency virus , hepatitis B C virus positive Subjects suffer clinically important systematic disease , hypothalmic pituitary tumour , ovarian , uterine breast cancer , endocrinopathy and/or medical alteration , biochemical hematological per investigator judgement , may interfere gonadotropin treatment Subjects subject 2 assisted reproductive cycle past Subjects cancel 2 cycle past Subjects cryopreserved embryos previous assist reproductive cycle Subjects non explain vaginal haemorrhage Subjects polycystic ovary , enlarge ovary ovarian cyst unknown aetiology Subjects contraindication get pregnant take pregnancy full term Subjects know allergy gonadotropin preparation excipients Subjects current drug use prior personal history alcohol , drug psychiatric drug dependency past five year Subjects prior participation study simultaneous participation different clinical study medication investigation Subjects willing incapable follow study protocol</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Reproductive technology , Assisted</keyword>
	<keyword>Recombinant human follicle stimulate hormone ( r-hFSH )</keyword>
	<keyword>Recombinant leutinizing hormone ( r-hLH )</keyword>
	<keyword>Ovulation induction</keyword>
	<keyword>Infertility</keyword>
</DOC>